R&D channel feed – Endpoints News

R&D channel feed

CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

3 years ago

Novartis takes another stride toward Alexion's turf with PhIII PNH win

3 years ago

New industry report suggests UK clinical trial research recruitment is in massive decline

3 years ago

Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug

3 years ago

Updated: With new $100M investment, a biotech with two approved drugs spins out its manufacturing business

3 years ago

As links to MS deepen, researchers accelerate efforts to develop an Epstein-Barr vaccine

3 years ago

Immunic reports another trial flop, and execs blame 'confounded' placebo response as shares sink

3 years ago

Updated: A New Jersey biotech shuffles C-suite, halts promotion of yeast infection drug and lays off employees

3 years ago

Four months after implementing new PhIII safety protocol, organ transplant biotech reports patient death

3 years ago

AM-Pharma flies white flag on PhIII battle, but they aren't giving up on their kidney drug

3 years ago

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

3 years ago

Two public biotechs seek to merge, focusing on desmoid tumors. But Nasdaq is not guaranteed

3 years ago

Biotech layoffs continue as Ambrx cuts staff and part of its pipeline to extend its cash

3 years ago

Backed by OrbiMed, Sanofi vet's startup tackles the many mutations of breast cancer at once

3 years ago

Updated: In new speed bump for Huntington's, FDA pauses PTC's PhII trial

3 years ago

Scoop: After hep B setback, an OrbiMed-backed NASH biotech hunts for partners as it raises Series C

3 years ago

J&J holds off on volatile M&A market but has plenty of cash for a deal

3 years ago

Where CAR-Ts were in 2012? Former Tmunity CEO Oz Azam unveils not-quite-a-psychedelics biotech

3 years ago

Roche cuts PhII eye disease program, one day after another biotech flopped in same indication

3 years ago

Houston startup pauses enrollment in pediatric cancer trial after patient death

3 years ago

Tale of two SPACs: One strikes a deal as turbulent market forces another to dissolve

3 years ago

Apnimed touts PhIIb data for lead sleep apnea program, preparing to advance to pivotal studies

3 years ago

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

3 years ago

Merck partner NGM Bio takes stock beating after PhII failure in late-stage eye disease

3 years ago

First page Previous page 114 115 116117118 119 120 Next page Last page